Examinando por Materia "Síndrome de Ehlers-Danlos"

Seleccione resultados tecleando las primeras letras
Mostrando 1 - 1 de 1
  • Miniatura
    PublicaciónAcceso abierto
    Tratamientos farmacológicos y complementarios/alternativos en pacientes diagnosticados con síndrome de Ehlers-Danlos hipermóvil o tipo III (SED-III). Lima Metropolitana – 2023
    (Universidad Privada Norbert Wiener, 2023-11-20) Takahashi Ferrer, Carolina Mayo; Parreño Tipián, Juan Manuel
    Hypermobile Ehlers-Danlos Syndrome (hEDS or SED-III) is a Rare and Orphan Disease (ROD), a degenerative genetic condition with no precise diagnosis and no cure. According to the WHO, around 7% of the global population has a ROD. The objective was to analyze the most commonly used pharmacological and complementary/alternative treatments in patients diagnosed with hEDS, one of the RODs. Methodology: Quantitative approach, inductive method, basic type, non-experimental design, prospective study, cross-sectional cut, and descriptive scope. The sample consisted of 38 patients diagnosed with hEDS. A self-developed questionnaire was applied. Results: Among complementary/alternative treatments, the most used were Biological Therapies, with Vitamins being the most employed. Twenty-eight patients reported symptom improvement, and three reported no effect. Among pharmacological treatments, the most used drug group was NSAIDs, with Diclofenac being the most frequently used. Twenty-two patients reported symptom improvement, and three reported no effect. Conclusion: The most commonly used treatment was complementary/alternative (Vitamins), compared to pharmacological treatments (Diclofenac).